As #CancerImmunotherapyMonth comes to a close, we remain committed to discovering new approaches to cancer immunotherapy that open the door to potential novel treatments for patients in need. At Arcus, we have focused on building exceptional small molecule, medicinal chemistry and antibody capabilities to optimize the combinability of molecules within our portfolio. Learn from our President Juan Jaen and CMO Dimitry Nuyten about how we are targeting the #adenosineaxis to harness the body’s own immune system to attack and destroy #coloncancer: https://bit.ly/3VbWzJg
Arcus Biosciences’ Post
More Relevant Posts
-
With the 2024 ASCO® Annual Meeting approaching at the end of the month, our experts are digging into the key theme of the congress. The theme of the meeting is "The Art and Science of Cancer Care: From Comfort to Cure.” The focus on antibody drug conjugates (ADCs) exemplifies the theme's "science" aspect, showcasing how ‘targeted’ chemotherapies are revolutionizing treatment. Meanwhile, the emphasis on early therapeutic intervention in cancer, applications of ctDNA highlight the "art" of addressing patient comfort and improving outcomes. What are you most interested in hearing? #ASCO24 #CancerResearch
-
-
Exploring the frontier of cancer research: A glimpse into the promising world of targeted drug therapies that are revolutionizing our approach to combating cancer. Stay informed, stay hopeful. #CancerResearch #TargetedTherapy #HealthcareInnovation #ShenClinicalServices
-
Are you attending the Immuno by Oxford Global Conference (Immuno 2024) starting on Thursday in #London? Don’t miss out on the presentation by our VP Preclinical Research & Translation Strategy, Thorsten Ross , on April 26. He will speak about the role of GDF-15 in #cancer therapy resistance and how blocking GDF-15 can boost current standard-of-care and emerging treatments & improve #patient outcomes. The talk includes recent insights about our lead candidate visugromab, a first-in-class GDF-15-neutralizing antibody, currently being evaluated in Phase 2 clinical trials. Download the full conference program here https://bit.ly/3UhM5I6 & learn more about our novel approach to tackling cancer resistance at www.catalym.com #OGImmuno #Immuno24
-
-
It's great to see Fierce Pharma and Bio-Techne as excited about exosomes as we are! Their white paper reinforces what we say daily: There is an unmet medical need for early cancer detection and #exosomes are key to meeting that need. Exosomes have the potential to identify a range of clinical needs, such as detecting cancer early, distinguishing from benign conditions, and identifying fast- and slow-growing cancers. Learn more>https://bit.ly/48gqIuQ #earlydetection #earlydetectioniskey #exosomesresearch
-
-
President at Healing Works Foundation | Bestselling author of #HowHealingWorks | Practicing family physician | Co-author of Healing and Cancer: A Guide to Whole Person Care, available April 2024
Did you know honey bees could revolutionize cancer detection? New research shows they can identify cancer biomarkers with 88% accuracy, offering a glimpse into the future of noninvasive diagnostics. This could lead to simple breath tests for early detection, significantly improving patient outcomes by catching cancer sooner. Such advancements support the whole person care approach by reducing invasive procedures and stress. Dive into this fascinating study and envision a new horizon in oncology: https://bit.ly/4cl5ZHI #WholePersonCare #InnovativeDiagnostics #CancerResearch
-
-
At Labcorp, we're using flow cytometry testing to detect patient immune responses to CAR T-cell cancer therapy. Unlike traditional ELISA methods, this approach analyzes antibodies against the full CAR protein in its native membrane environment, providing a more valid immunogenicity assessment to support treatment safety and efficacy. Read our scientific poster to learn how Labcorp is advancing CAR T-cell therapy: https://lnkd.in/eT3xb2cy #FlowCytometry #AntidrugAntibodies #CellTherapy #CellandGeneTherapy
-
-
March is #ColorectalCancerAwarenessMonth. Advanced BioDesign is dedicated to search for new therapeutics alternative to treat this cancer which is the third most prevalent cancer among men and the second in women globally. Strengthened by our collaboration with the team led by Bassam Janji (PhD, HDR) at Luxembourg Institute of Health, significant progress has been made in the development of the second generation ALDH inhibitor, #ABD0171, which exhibits promising synergistic effects with immunotherapy. Together, we have achieved transformative results, potentially pioneering a strategy to convert immunotherapy-resistant advanced CRC tumors into responders! #ColorectalCancerAwarenessMonth #cancerresistance
-
At Labcorp, we're using flow cytometry testing to detect patient immune responses to CAR T-cell cancer therapy. Unlike traditional ELISA methods, this approach analyzes antibodies against the full CAR protein in its native membrane environment, providing a more valid immunogenicity assessment to support treatment safety and efficacy. Read our scientific poster to learn how Labcorp is advancing CAR T-cell therapy: https://lnkd.in/eT_MH-ve #FlowCytometry #AntidrugAntibodies #CellTherapy #CellandGeneTherapy
-
-
Did you know honey bees could revolutionize cancer detection? New research shows they can identify cancer biomarkers with 88% accuracy, offering a glimpse into the future of noninvasive diagnostics. This could lead to simple breath tests for early detection, significantly improving patient outcomes by catching cancer sooner. Such advancements support the whole person care approach by reducing invasive procedures and stress. Dive into this fascinating study and envision a new horizon in oncology: https://bit.ly/4cl5ZHI #WholePersonCare #InnovativeDiagnostics #CancerResearch
-
